ESCC

This study tests a new approach for people with locally advanced esophageal cancer. Participants first receive a combination of immunotherapy and chemotherapy, then chemoradiation, followed by surgery. The goal is to see if this sequence can shrink tumors more effectively and imp…

This early-stage trial tests NRM-823, a drug designed to help the immune system fight cancer, in 150 people with advanced solid tumors like lung, breast, and ovarian cancer. The study gives NRM-823 alone or with another immunotherapy to see if it is safe and tolerable. The main g…

This early-stage study is testing a new drug called ALX2004 in people with advanced lung, head and neck, esophageal, or colorectal cancers that have not responded to standard treatments. ALX2004 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly t…

This study tests whether giving two drugs (anlotinib and bemocizumab) before surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma. About 25 adults with stage II-IIIB disease will receive the combination, then undergo surgery. The main goal is…

This study tests a new drug called JAB-8263 in adults with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 152 people will take part in this early-phase trial.

This study is developing a new blood test to find esophageal cancer at an early, more treatable stage. Researchers will analyze tiny particles in the blood of 600 adults with and without the disease. The goal is to create a simple, non-invasive screening tool that could replace u…